#Helus
LightNews LightNews
merlintrader.bsky.social
Helus Pharma #$HELP will present at the Guggenheim conference in Boston.

CEO Michael Halstead presents on Nov 9 at 3:00 p.m. ET.

Shares closed at $8.80 Mon: below SMA50, above SMA200, RSI 32.

Hub: www.merlintrader.com/helus-pharma...

Not investment advice.
HELP Stock: Helus Pharma News, APPROACH & HLP004
Helus Pharma stock news and analysis: the APPROACH Phase 3 program, the HLP004 pipeline in anxiety and depression, cash and dilution risks for HELP holders.
www.merlintrader.com
November 3, 2026 at 4:52 PM
stocktitan.net
#HELP Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference

https://www.stocktitan.net/news/HELP/helus-pharma-to-participate-in-the-guggenheim-healthcare-innovation-m51od5w6m5s5.html?utm_source=stocktitan-bluesky&utm_medium=social
Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference
Helus Pharma (HELP) will participate in the Guggenheim Healthcare Innovation Conference in Boston on November 9, 2026. Chief Executive Officer Michael Halstead will join a fireside chat, webcast live at 3:00 p.m. EDT. A replay will be available on the Events & Presentations page of the company’s investor relations website.
www.stocktitan.net
November 3, 2026 at 12:30 PM
newsramp.com
Helus Pharma (NASDAQ: HELP) appoints Mark Lawson as independent board chair as co-founders transition out of executive roles. The clinical-stage company targets Phase 3 topline data for its depression treatment HLP003 in Q4 2026. #MentalHealth #Pharma
Image from article
November 4, 2026 at 11:30 PM
notreload.bsky.social
Psychedelic Alpha reports Usona has likely filed an NDA for psilocybin in major depression, intensifying competition with #$CMPS and other developers. #$DFTX, #$HELP, #$GHRS notreload.xyz/xy/usona-psi...
Usona Psilocybin NDA Filing Intensifies Competition
Usona’s potential FDA filing for psilocybin makes the competitive landscape more real for Compass, Definium, Helus Pharma and GH Research, analyst says.
notreload.xyz
November 2, 2026 at 8:37 PM
newsramp.com
Helus Pharma (NASDAQ: HELP) CEO Michael Halstead will speak at the Guggenheim Healthcare Innovation Conference in Boston on Nov. 9, 2026. The company is advancing FDA Breakthrough-designated HLP003 for major depressive disorder. #MentalHealth #Pharma
Image from article
November 4, 2026 at 9:42 PM
newsramp.com
Helus Pharma (NASDAQ: HELP) appoints CNS veteran Suresh Durgam, former CMO of Intra-Cellular Therapies, to its board as it pushes HLP003 through Phase 3 for major depressive disorder with FDA Breakthrough Therapy Designation. #MentalHealth #Pharma
Image from article
November 3, 2026 at 8:04 PM
merlintrader.bsky.social
#$HELP weekly close $10.60 (+4.0% w/w), below SMA50 $11.96 / above SMA200 $7.71, RSI 44.7. Support $9.71, resistance $12.73. Broad market sell-off Friday.

New hub updated: www.merlintrader.com/helus-pharma...
October 31, 2026 at 11:31 AM
merlintrader.bsky.social
$HELP Helus Pharma expects APPROACH Phase 3 topline results for HLP003 in Q4 2026, after completing enrollment on July 21.

https://www.merlintrader.com/helus-pharma-help-stock-hub/
HELP Stock: Helus Pharma News, APPROACH & HLP004
Helus Pharma stock news: APPROACH Phase 3 topline is expected in Q4 2026; HLP004 Phase 2 monotherapy in GAD is planned for Q1 2027.
www.merlintrader.com
October 28, 2026 at 10:50 PM
merlintrader.bsky.social
$HELP Next: APPROACH topline, guided to Q4 2026. Oct 27: co-founders left executive roles but stay on the board; independent Chair. Rebuilt hub with the 23-page PDF report. Not investment advice.

https://www.merlintrader.com/helus-pharma-help-stock-hub/?v=snello
HELP Stock: Helus Pharma News, APPROACH & HLP004
Helus Pharma stock news: APPROACH Phase 3 topline is expected in Q4 2026; HLP004 Phase 2 monotherapy in GAD is planned for Q1 2027.
www.merlintrader.com
October 30, 2026 at 12:34 AM
merlintrader.bsky.social
#$HELP weekly close $10.60 (+4.0% w/w), below SMA50 $11.96 / above SMA200 $7.71, RSI 44.7. Support $9.71, resistance $12.73. Broad market sell-off Friday.

New hub updated: www.merlintrader.com/helus-pharma...
October 31, 2026 at 11:31 AM
merlintrader.bsky.social
$HELP Helus Pharma expects APPROACH Phase 3 topline results for HLP003 in Q4 2026, after completing enrollment on July 21.

https://www.merlintrader.com/helus-pharma-help-stock-hub/
HELP Stock: Helus Pharma News, APPROACH & HLP004
Helus Pharma stock news: APPROACH Phase 3 topline is expected in Q4 2026; HLP004 Phase 2 monotherapy in GAD is planned for Q1 2027.
www.merlintrader.com
October 28, 2026 at 10:50 PM
merlintrader.bsky.social
$HELP Next: APPROACH topline, guided to Q4 2026. Oct 27: co-founders left executive roles but stay on the board; independent Chair. Rebuilt hub with the 23-page PDF report. Not investment advice.

https://www.merlintrader.com/helus-pharma-help-stock-hub/?v=snello
HELP Stock: Helus Pharma News, APPROACH & HLP004
Helus Pharma stock news: APPROACH Phase 3 topline is expected in Q4 2026; HLP004 Phase 2 monotherapy in GAD is planned for Q1 2027.
www.merlintrader.com
October 30, 2026 at 12:34 AM
stocktitan.net
#HELP Helus Pharma Announces Co-Founders’ Transition from Executive Leadership as Company Advances Toward Next Stage of Development

https://www.stocktitan.net/news/HELP/helus-pharma-announces-co-founders-transition-from-executive-9v11mqqkmvv9.html?utm_source=stocktitan-bluesky&utm_medium=social
Helus Pharma Announces Co-Founders’ Transition from Executive Leadership as Company Advances Toward Next Stage of Development
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 27, 2026 at 12:00 PM
merlintrader.bsky.social
$HELP — Co-founders leave executive roles; new independent chair. Phase 3 APPROACH topline confirmed for Q4 2026.

Information only — not investment advice.

https://www.merlintrader.com/helus-pharma-help-stock-hub/
HELP Just Charts card
October 27, 2026 at 5:55 PM
nexusfinance.bsky.social
💊 Universe Pharmaceuticals stock up 14.6% to $3.3 pre-market
📈 Tata Capital Q2 net profit jumps 51% to Rs 1,660 crore
👥 Helus Pharma co-founders transition from executive roles
💊 Teva acquires worldwide rights to BXCL501 film
October 27, 2026 at 5:53 PM
merlintrader.bsky.social
$HELP Latest company news, Oct 21, 2026: at its investor event Helus confirmed APPROACH Phase 3 topline for Q4 2026, with 223 patients enrolled, and an NDA expected in 2028.

https://www.merlintrader.com/helus-pharma-help-stock-hub/
Helus Pharma $HELP: HLP003 And The Phase 3 MDD Test
Helus Pharma develops HLP003 for depression. Explore the APPROACH Phase 3 catalyst, early evidence, cash, dilution and clinical risks.
www.merlintrader.com
October 22, 2026 at 3:59 PM
merlintrader.bsky.social
🎓 What does Helus Pharma #$HELP actually do? 2-minute educational walkthrough: HLP003 in adjunctive depression, the APPROACH Phase 3 study and key dated figures.
▶️ www.youtube.com/watch?v=UiaO...
Educational only, not financial advice.
October 23, 2026 at 5:08 PM
stocktitan.net
#HELP Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026

https://www.stocktitan.net/news/HELP/helus-pharma-highlights-clinical-program-advancements-at-investor-adcwqf2h8hfx.html?utm_source=stocktitan-bluesky&utm_medium=social
Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 21, 2026 at 8:10 PM
merlintrader.bsky.social
October 15, 2026: Helus Pharma named Dr. Suresh Durgam, ex-Intra-Cellular CMO, to its board. APPROACH Phase 3 topline for HLP003 in MDD expected Q4 2026; investor presentation Oct 21. $HELP

https://www.merlintrader.com/helus-pharma-help-stock-hub/
Helus Pharma $HELP: HLP003 And The Phase 3 MDD Test
Helus Pharma develops HLP003 for depression. Explore the APPROACH Phase 3 catalyst, early evidence, cash, dilution and clinical risks.
www.merlintrader.com
October 16, 2026 at 7:54 AM
stahworsbot.bsky.social
"Did you ever hear the folklore of Darth Helus the Fantastic?

I thought not. It's not a story the Empire Reborn would tell you."
— Darth Tyranus
October 16, 2026 at 4:25 PM
stock-bot.bsky.social
Random Stock
Ticker: $HELP
Company: Cybin D/B/A Helus Pharma
Sector: Healthcare
Industry: Biotechnology
# Employees: 100
Recent Close: $11.80
52-Week High: $15.15
52-Week High Date: 09-18-2026
% Off 52-Week High: -22.11%
52-Week Low: $3.76
October 11, 2026 at 11:00 PM
newsramp.com
Helus Pharma (NASDAQ: HELP) will host an investor presentation on Oct. 21 highlighting its Phase 3 depression drug HLP003 and Phase 2 anxiety candidate HLP004. Key opinion leaders and a live Q&A with executives are on the agenda. #MentalHealth #Biotech
Image from article
October 10, 2026 at 6:32 PM
stahworsbot.bsky.social
"Did you ever hear the gospel of Darth Tenebrate the Desirable?

I thought not. It's not a story the Lands Fixated On Northes Movement would tell you."
— Darth Helus Ruuma
October 9, 2026 at 10:15 PM
newsramp.com
Helus Pharma (NASDAQ: HELP) officially changes its legal name from Cybin Inc., effective Oct. 1, as shareholders back the company's transformation into a commercial-ready pharmaceutical company targeting depression and anxiety. #MentalHealth #Pharma
Image from article
October 9, 2026 at 6:19 PM
newsramp.com
Helus Pharma (NASDAQ: HELP) officially changes its legal name from Cybin Inc., effective Oct. 1, as shareholders back the company's transformation into a commercial-ready pharmaceutical company targeting depression and anxiety. #MentalHealth #Pharma
Image from article
October 9, 2026 at 6:19 PM